Company intelligence / Profile preview

Yposkesi

Corbeil-Essonnes / Évry, Île-de-France, France

Ownership: Private
Employees: ~185
Development stage: Other

Overview

Yposkesi does not run its own clinical programs; it manufactures for third parties’ programs. It rapidly scaled viral vector manufacturing for gene and cell therapies, doubling footprint in 2024 to become one of Europe's largest facilities. Success is measured in delivery and operational capacity, not through clinical trial outcomes[1][2][4][6].

Therapeutic areas: HematologyCritical CareRare Diseases
Modalities: Gene therapyCell therapyViral vectorAdeno-associated virus (AAV)Lentiviral vector (LV)
Industry: Contract Manufacturing Organization

Partnerships

GenethonAFM-TéléthonCustomers include global biopharma; specific public partnerships not frequently disclosed

Beyond the preview

Go deeper on Yposkesi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yposkesi.

Explore the full profile